Technical Analysis for ALLR - Allarity Therapeutics, Inc.

Grade Last Price % Change Price Change
F 1.22 2.37% 0.03
ALLR closed down 4.8 percent on Wednesday, November 20, 2024, on 56 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 2.37%
180 Bearish Setup Bearish Swing Setup 2.37%
Bollinger Band Squeeze Range Contraction 2.37%
Lower Bollinger Band Walk Weakness 2.37%
BB Squeeze + Lower Band Touch Range Contraction 2.37%
Outside Day Range Expansion 2.37%
Below Lower BB Weakness 2.37%
Lower Bollinger Band Touch Weakness 2.37%
Oversold Stochastic Weakness 2.37%
Jack-in-the-Box Bearish Bearish Swing Setup -2.54%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 1 hour ago
Up 5% about 3 hours ago
Rose Above Lower Bollinger Band about 3 hours ago
Up 3% about 3 hours ago
Up 2% about 3 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Allarity Therapeutics, Inc. Description

Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Health Sciences Drugs Treatment Of Cancer Enzymes Protein Kinase Inhibitor Tyrosine Kinase Doxorubicin Liposome

Is ALLR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 660.0
52 Week Low 1.15
Average Volume 726,739
200-Day Moving Average 55.64
50-Day Moving Average 1.76
20-Day Moving Average 1.40
10-Day Moving Average 1.34
Average True Range 0.17
RSI (14) 29.58
ADX 18.1
+DI 16.76
-DI 24.02
Chandelier Exit (Long, 3 ATRs) 1.74
Chandelier Exit (Short, 3 ATRs) 1.67
Upper Bollinger Bands 1.58
Lower Bollinger Band 1.21
Percent B (%b) -0.06
BandWidth 26.53
MACD Line -0.18
MACD Signal Line -0.20
MACD Histogram 0.0245
Fundamentals Value
Market Cap 7.01 Million
Num Shares 5.89 Million
EPS 2625.43
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 0.00
Price-to-Book 2.35
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.37
Resistance 3 (R3) 1.38 1.33 1.34
Resistance 2 (R2) 1.33 1.28 1.33 1.33
Resistance 1 (R1) 1.26 1.26 1.24 1.25 1.32
Pivot Point 1.21 1.21 1.20 1.21 1.21
Support 1 (S1) 1.14 1.16 1.12 1.13 1.06
Support 2 (S2) 1.09 1.14 1.09 1.05
Support 3 (S3) 1.02 1.09 1.04
Support 4 (S4) 1.01